Beam Therapeutics (BEAM) Stock Analysis & AI Equity Report
Beam Therapeutics (BEAM) overview
Beam Therapeutics (BEAM) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 140m and operating profit of USD -384m; the year-end share price was 27.72 USD and market capitalisation was USD 2,820m. Beam Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Beam Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Beam Therapeutics
Beam Therapeutics is a biotechnology company developing precision genetic medicines using gene editing and delivery technologies, including proprietary base editing. Its programs address hematology and genetic diseases, with investigational therapies and delivery platforms designed for different tissues and treatment approaches. The company also has internal manufacturing capabilities. Its work is directed toward potential treatments for patients with serious diseases.
Generate the Beam Therapeutics report
Beam Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Beam Therapeutics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Beam Therapeutics
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.